Thermo Fisher Scientific Launches Next-Generation Cell Line Development Platform to Accelerate Biologics Manufacturing
核心洞察
Thermo Fisher Scientific (搜索) announced the Gibco CHOvantage GS Cell Line Development Kit (搜索), a next-generation integrated platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability.
The platform achieves protein titers of ≥7 g/L in fed-batch cultures, establishes stable pools in as little as four weeks, and supports selection of stable clones within 14 weeks.
OneCyte (搜索) and Kemp Proteins (搜索) formed a strategic partnership combining single-cell analysis technology with protein engineering capabilities to address challenges in developing complex biologics.
Thermo Fisher Scientific (搜索) Inc. announced a next-generation, integrated cell line development platform designed to help biologics developers accelerate time to clinic while maintaining regulatory confidence and commercial scalability. The Gibco CHOvantage GS Cell Line Development Kit (搜索) addresses mounting pressure on manufacturers to shorten development timelines, improve manufacturing consistency, and control costs without compromising quality or regulatory compliance.
The platform enables researchers to generate high-performing CHO cell lines, achieving protein titers of ≥7 g/L in fed-batch cultures. The system establishes stable pools in as little as four weeks and supports selection of stable clones within 14 weeks, streamlining progression from early development to commercial manufacturing.
Addressing Industry Pressures
Global pipelines for protein therapeutics, including complex biologics and biosimilars used to treat conditions ranging from cancer to autoimmune and rare diseases, continue to expand. This growth places increasing pressure on manufacturers while regulatory agencies emphasize demonstrating product quality and comparability to innovator molecules.
"Biologics developers face increasing pressure to deliver therapies faster while managing cost, quality and regulatory complexity," said Sara Henneman, vice president and general manager of Thermo Fisher Scientific (搜索)'s cell culture and cell therapy business. "With the CHOvantage GS CLD Kit, we're helping customers compress development timelines, increase confidence in quality and lower overall costs through a royalty-free, clinical-stage licensing model that helps minimize barriers to market."
Technical Innovation and Integration
The CHOvantage GS CLD Kit integrates a transposon-based vector system with Efficient-Pro media and feeds to provide a reliable, high-quality, streamlined platform. This harmonized workflow is designed to simplify tech transfer and enable smoother transitions from development to manufacturing.
"By integrating a transposon-based vector system with our Efficient-Pro media and feeds, we're giving customers a reliable, high-quality, streamlined platform that helps to save time, reduces variability and supports scalability," said Andy Campbell, senior director of research and development at Thermo Fisher Scientific (搜索).
Patent expirations are accelerating the development of lower-cost biosimilar medicines, increasing demand for reliable and scalable technologies that can help manufacturers bring treatments to market more quickly while maintaining strict quality and regulatory standards.
Industry Validation
BioFactura (搜索), a developer and manufacturer of high-value biosimilars and novel drugs, served as a key pre-launch testing partner for the platform. Lead Cell Line Development Scientist Carson Brackna stated, "Combining transposon vectors and optimized media and feeds, the CHOvantage platform offered a robust, end-to-end cell line package while remaining user-friendly and yielding quality protein with high productivity on a tight schedule."
Strategic Partnership Addresses Complex Biologics
In a related development, OneCyte (搜索) and Kemp Proteins (搜索) announced a strategic partnership to deliver industry-leading cell line development services for biopharmaceutical companies worldwide. The collaboration combines OneCyte's proprietary single-cell platform for high-throughput, high-sensitivity, and high-speed clone selection with Kemp Proteins' advanced molecular engineering capabilities, including its proprietary machine learning-driven platform, PROTiQ.
Biopharma companies continue to face significant challenges in cell line development, including long development cycles, suboptimal yields, and high failure rates, particularly for novel and complex molecules. These challenges can delay regulatory timelines and slow the progression of therapies into the clinic.
The partnership integrates predictive in silico design with rapid and high throughput experimental validation. Amino acid sequences are evaluated using Kemp's PROTiQ platform to assess developability risks, identify sequence liabilities, and generate structural insights. These optimized candidates are then paired with OneCyte (搜索)'s high-performance cell line development platform for rapid identification of elite clones with superior productivity.
"We are thrilled to be working with Kemp to provide industry-leading cell line development services to the biopharma industry," said Dr. Konstantinos Tsioris, co-founder and president of OneCyte (搜索). "By combining our single-cell technology with Kemp's deep expertise in protein expression, we are confident that we can address the hardest challenges associated with new modalities, delivering faster timelines and industry-leading titers."
The combined offering provides access to a royalty-free CHO-K1 GS (搜索) knockout cell line and transposase-based expression system, enabling flexible and efficient development without restrictive licensing constraints. This integrated approach is designed to adapt quickly to the evolving needs of new therapeutic modalities, delivering both speed and performance without compromise.